Table 1. Characteristics of and Outcomes in Cohorts With SARS-CoV-2 Omicron, Influenza, or RSV Infectiona.
| Characteristics | Age 0-1 y | Age 2-4 y | Age 5-17 y | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Omicron (n = 648) | Influenza (n = 81) | RSV (n = 990) | Omicron (n = 81) | Influenza (n = 80) | RSV (n = 236) | Omicron (n = 167) | Influenza (n = 265) | RSV (n = 48) | |
| Sex | |||||||||
| Female | 306 (47.2) | 45 (55.6) | 440 (44.4) | 34 (42.0) | 46 (57.5) | 113 (47.9) | 77 (46.1) | 124 (46.8) | 21 (43.8) |
| Male | 342 (52.8) | 36 (44.4) | 550 (55.6) | 47 (58.0) | 34 (42.5) | 123 (52.1) | 90 (53.9) | 141 (53.2) | 27 (56.2) |
| Age, median (IQR), y | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 3.0 (2.0-3.0) | 3.0 (2.0-4.0) | 2.0 (2.0-3.0) | 10.0 (7.0-13.5) | 10.0 (7.0-14.0) | 7.0 (5.0-10.0) |
| Comorbidities | |||||||||
| Asthma | 6 (0.9) | 4 (4.9) | 20 (2.0) | 19 (23.5) | 23 (28.7) | 74 (31.4) | 39 (23.4) | 60 (22.6) | 20 (41.7) |
| Cancer | 1 (0.2) | 0 | 0 | 6 (7.4) | 2 (2.5) | 2 (0.8) | 12 (7.2) | 5 (1.9) | 6 (12.5) |
| Cardiac disease | 5 (0.8) | 0 | 6 (0.6) | 1 (1.2) | 1 (1.2) | 7 (3.0) | 4 (2.4) | 6 (2.3) | 3 (6.2) |
| Chronic kidney disease | 0 | 0 | 0 | 1 (1.2) | 0 | 0 | 0 | 2 (0.8) | 1 (2.1) |
| Chronic respiratory disease, not asthma | 4 (0.6) | 0 | 4 (0.4) | 4 (4.9) | 5 (6.2) | 6 (2.5) | 10 (6.0) | 10 (3.8) | 18 (37.5) |
| Congenital malformations and abnormalities | 100 (15.4) | 10 (12.3) | 130 (13.1) | 22 (27.2) | 22 (27.5) | 69 (29.2) | 44 (26.3) | 64 (24.2) | 19 (39.6) |
| Type 1 or 2 diabetes | 0 | 0 | 0 | 1 (1.2) | 2 (2.5) | 0 | 4 (2.4) | 3 (1.1) | 0 |
| Immunocompromised | 7 (1.1) | 0 | 1 (0.1) | 9 (11.1) | 5 (6.2) | 13 (5.5) | 26 (15.6) | 18 (6.8) | 10 (20.8) |
| Perinatal conditions | 149 (23.0) | 12 (14.8) | 218 (22.0) | 25 (30.9) | 18 (22.5) | 75 (31.8) | 24 (14.4) | 32 (12.1) | 11 (22.9) |
| Any | 215 (33.2) | 22 (27.2) | 304 (30.7) | 51 (63.0) | 45 (56.2) | 158 (66.9) | 95 (56.9) | 133 (50.2) | 39 (81.2) |
| Outcomes | |||||||||
| Hospital admission | 203 (31.3) | 34 (42.0) | 825 (83.3) | 34 (42.0) | 17 (21.2) | 181 (76.7) | 45 (26.9) | 67 (25.3) | 35 (72.9) |
| Hospital length of stay, median (IQR), d | 2.0 (1.0-3.0) | 1.0 (1.0-2.0) | 4.0 (3.0-6.0) | 2.0 (1.0-2.8) | 2.0 (1.0-4.0) | 2.0 (1.0-3.0) | 3.0 (1.0-5.0) | 2.0 (1.0-4.0) | 2.0 (1.0-4.0) |
| High-flow nasal cannula | 13 (2.0) | 1 (1.2) | 350 (35.4) | 6 (7.4) | 2 (2.5) | 15 (6.4) | 6 (3.6) | 7 (2.6) | 6 (12.5) |
| BiPAP, CPAP, or NIV | 0 | 0 | 57 (5.8) | 0 | 0 | 0 | 2 (1.2) | 1 (0.4) | 3 (6.2) |
| ICU admission | 2 (0.3) | 0 | 34 (3.4) | 1 (1.2) | 0 | 2 (0.8) | 3 (1.8) | 4 (1.5) | 1 (2.1) |
| Mechanical ventilation | 1 (0.2) | 0 | 1 (0.1) | 0 | 0 | 0 | 0 | 0 | 0 |
| 30-d All-cause mortality | 0 | 0 | 0 | 0 | 0 | 0 | 2 (1.2) | 0 | 1 (2.1) |
Abbreviations: BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; ICU, intensive care unit; NIV, noninvasive ventilation; RSV, respiratory syncytial virus.
a
Data are presented as number (percentage) of individuals unless otherwise indicated.